Copenhagen, Denmark – October 4, 2016: IO Biotech today announced that industry veteran Dr Peter Hirth will succeed Dr Hans Schambye as Chairman of the Board of Directors. IO Biotech develops novel therapeutic immuno-oncology vaccines targeting immune check point inhibitory targets to treat cancer.
Dr Jérôme Galon, Research Director at Inserm, Head of the laboratory of Integrative Cancer Immunology, Paris, France, and Scientific Advisor of IO Biotech presented at ASCO 2016 the very positive results of the international initiative, the Immunoscore® study. The assay was developed to predict the ability of a person’s immune system to fight tumor cells and its performance has already been documented in a number of studies for its ability to predict recurrence in colon cancer.
IO Biotech has been granted an Industrial PhD project entitled 'Characterisation of a PD-L1-based cancer vaccine in vivo' from Innovation Fund Denmark. The Industrial PhD will be performed in collaboration with Department of Immunology and Microbiology, University of Copenhagen, between June 2016 and June 2019.